706 related articles for article (PubMed ID: 27552339)
21. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer.
Zeng Z; Wang ZY; Li YK; Ye DM; Zeng J; Hu JL; Chen PF; Xiao J; Zou J; Li ZH
Life Sci; 2020 Aug; 254():117325. PubMed ID: 31954159
[TBL] [Abstract][Full Text] [Related]
22. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D; Motoike IN; Saito S; Zorzi M; Aoki Y; Kitamura H; Suzuki M; Katsuoka F; Ishii H; Kinoshita K; Motohashi H; Yamamoto M
Cancer Sci; 2020 Feb; 111(2):667-678. PubMed ID: 31828882
[TBL] [Abstract][Full Text] [Related]
23. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
24. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
[TBL] [Abstract][Full Text] [Related]
25. Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks.
Xu K; Ma J; Hall SRR; Peng RW; Yang H; Yao F
Theranostics; 2023; 13(2):704-723. PubMed ID: 36632216
[TBL] [Abstract][Full Text] [Related]
26. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
27. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
28. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
[TBL] [Abstract][Full Text] [Related]
29. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ
J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114
[TBL] [Abstract][Full Text] [Related]
30. PPIA dictates NRF2 stability to promote lung cancer progression.
Lu W; Cui J; Wang W; Hu Q; Xue Y; Liu X; Gong T; Lu Y; Ma H; Yang X; Feng B; Wang Q; Zhang N; Xu Y; Liu M; Nussinov R; Cheng F; Ji H; Huang J
Nat Commun; 2024 Jun; 15(1):4703. PubMed ID: 38830868
[TBL] [Abstract][Full Text] [Related]
31. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.
DeBlasi JM; Falzone A; Caldwell S; Prieto-Farigua N; Prigge JR; Schmidt EE; Chio IIC; Karreth FA; DeNicola GM
Cancer Res; 2023 Jun; 83(12):1953-1967. PubMed ID: 37062029
[TBL] [Abstract][Full Text] [Related]
32. Role of NRF2 in Lung Cancer.
Sánchez-Ortega M; Carrera AC; Garrido A
Cells; 2021 Jul; 10(8):. PubMed ID: 34440648
[TBL] [Abstract][Full Text] [Related]
33. Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2.
Sun X; Dong M; Gao Y; Wang Y; Du L; Liu Y; Wang Q; Ji K; He N; Wang J; Zhang M; Gu Y; Song H; Zhai H; Feng L; Xu C; Liu Q
Biochem Pharmacol; 2022 May; 199():114981. PubMed ID: 35227644
[TBL] [Abstract][Full Text] [Related]
34. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
35. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
36. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
37. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
38. Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.
Vartanian S; Ma TP; Lee J; Haverty PM; Kirkpatrick DS; Yu K; Stokoe D
Mol Cell Proteomics; 2016 Apr; 15(4):1220-31. PubMed ID: 26711467
[TBL] [Abstract][Full Text] [Related]
39. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
40. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
